Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
(2020)
Journal Article
Shah, M., Maroof, A., Gikas, P., Mittal, G., Keen, R., Baeten, D., Shaw, S., & Roberts, S. J. (2020). Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open, 6(2), e001306. https://doi.org/10.1136/rmdopen-2020-001306
Objectives
Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understo...
Read More about Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.